25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
On August 12, 2019, Governor Andrew Cuomo signed Assembly Bill A8421 / Senate Bill 6577 (“Law”), w...
Read More >
Owners and developers with construction projects underway are understandably very concerned about th...
Read More >
Q. I heard there have been some significant National Labor Relations Board decisions recently. What...
Read More >
Maintaining records to meet the burden of proof and demonstrate causation in your construction claim...
Read More >
On September 24, 2019, the U.S Department of Labor announced the final rule on employee eligibility ...
Read More >
Colorado employers should review and, if necessary, revise job applications to remove questions abou...
Read More >